Introduction {#Sec1}
============

To avoid complications after percutaneous coronary intervention (PCI), such as acute and late thrombosis at the site of stenting and recurrent ischemic cardiovascular events, anti-platelet therapy is crucial \[[@CR1]\]. Several studies \[[@CR2]--[@CR4]\] have shown that dual anti-platelet therapy with aspirin and a thienopyridine ADP-receptor blocker is effective in preventing such acute and late complications. Clopidogrel is an ADP-receptor blocker that is used regularly in Japan. It has a better safety profile than ticlopidine, a previous-generation ADP-receptor blocker, but its main disadvantage is the wide interindividual variations of its anti-platelet effect \[[@CR5]\]. Hoshino et al. evaluated the anti-platelet effect of clopidogrel in Japanese patients and found wide interindividual variation as well as a proportion (approximately 14%) of clopidogrel non-responders \[[@CR6]\].

Prasugrel is a next-generation thienopyridine anti-platelet agent that has been approved in over 80 countries for patients with acute coronary syndrome (ACS) undergoing PCI. Prasugrel provides more prompt, potent, and consistent platelet inhibition than clopidogrel, and the effects of prasugrel are not influenced by the presence of CYP2C19 polymorphisms \[[@CR7]\]. The efficacy and safety of prasugrel were confirmed in Japanese patients in two phase III studies \[[@CR8], [@CR9]\]. Based on these results, prasugrel was approved in Japan in March 2014 for ACS \[including unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI)\], stable angina, and old myocardial infarction that requires PCI. The approved doses of prasugrel, which are exclusive for Japanese patients, are 20 mg as the initial loading dose (LD) and 3.75 mg/day as the maintenance dose (MD), which are lower than those used in Western countries (LD/MD: 60/10 mg/day). Given the higher average age and lower body weight of Japanese patients compared with Western patients, we considered that lower doses of prasugrel may effectively lower the risk of bleeding during dual anti-platelet therapy in Japanese patients while maintaining more consistent platelet inhibition than clopidogrel.

At present, data on the safety and efficacy of prasugrel in Japanese patients are limited to the populations of the phase II/III clinical trials, in which patients were selected based on strict inclusion criteria. In addition, because bleeding adverse events (AEs) have been reported as the most common adverse drug reactions (ADRs) in clinical trials, safety information should be made available in clinical settings as soon as possible by determining the incidence and severity of bleeding AEs under actual conditions of use. Therefore, this early postmarketing observational study (PRASFIT-Practice I) aimed to evaluate the safety and efficacy of the short-term use of prasugrel in patients with ACS in real-world clinical practice settings in Japan.

Methods {#Sec2}
=======

Study method {#Sec3}
------------

Briefly, this study was conducted as a postmarketing observational study in accordance with the Good Postmarketing Study Practice Guideline (Ministry of Health, Labour and Welfare Ordinance No. 171). At each institution, consecutive patients who met the inclusion criteria were enrolled prospectively. To gather as much information as possible in the period immediately after launch, retrospective data were collected for patients treated with prasugrel before the conclusion of the contract with each institution.

All 98 participating institutions approved the study protocol. Case report forms (CRFs) were collected for each patient who started treatment with prasugrel at least 1 month before the end of the study period, between 27 May 2014 and 26 January 2015. Because all patients were to be followed up until the end of the study period (26 January 2015) regardless of completion or discontinuation of prasugrel treatment, the observation period varied for each patient. Patients with ACS who were to undergo or had recently undergone PCI and had started prasugrel treatment at least 1 month before the end of the study period were included in this study.

Dosage and administration {#Sec4}
-------------------------

Dosage and administration according to the Japanese prescription label of prasugrel are as follows: prasugrel should be initiated with a single 20-mg oral dose and then continued at a 3.75-mg once-daily oral dose as a maintenance dose \[[@CR10]\]. Prasugrel was administered as 3.75- and 5-mg tablets, in combination with aspirin (81--100 mg/day; up to 324 mg could be used as an LD). Patients receiving a prasugrel dose of 3.75 mg during approximately 5 days prior to PCI did not require an initial LD. The extent of the exposure to prasugrel and the timing of prasugrel administration (before, during, or after PCI) under the actual conditions of use were examined.

Study variables {#Sec5}
---------------

Patient demographics, clinical baseline characteristics, clinical findings assessed prior to prasugrel treatment (or before initial PCI), during hospitalization, and at discharge, and the final diagnosis of ACS were assessed. The extent of exposure to prasugrel was based on the time and date of administration of the LD, the MD, the daily dose, the duration of treatment, and continuation or discontinuation of treatment. Other variables assessed were use of other anti-platelet agents/anti-coagulants and other concomitant medications, invasive procedures other than PCI/coronary artery bypass graft, initial coronary angiography (CAG) findings if the patient underwent CAG, timing of prasugrel administration (before, during, or after PCI), vital signs, laboratory data, AEs, bleeding AEs, and cardiovascular events.

Safety and efficacy {#Sec6}
-------------------

The safety outcomes assessed were the incidence of ADRs, serious ADRs, and bleeding AEs. The incidence of bleeding AEs was also assessed by clinical characteristics. AEs were defined as any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease showing a temporal association with the use of the study drug, irrespective of whether it was considered to be related to the drug. ADRs were defined as AEs for which a relationship to prasugrel could not be ruled out. AEs or ADRs that satisfied the following criteria were classified as serious: an event which (1) results in death, (2) is life-threatening, (3) requires hospitalization or prolongation of hospitalization, (4) results in disability or significant incapacity, (5) has the potential to result in disability or significant incapacity, (6) is as serious as any of the outcomes listed above, or (7) causes a congenital anomaly or birth defect. Detailed definitions of bleeding and cardiovascular events are provided in Electronic Supplement 1. Regarding the incidence of bleeding AEs by clinical characteristics, we identified clinical characteristics potentially affecting the incidence of bleeding AEs by comparing patients with bleeding AEs with those without.

The efficacy outcomes were the incidence of major adverse cardiovascular events (MACE). MACE was defined as a composite of cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal ischemic stroke. All-cause death, non-fatal stroke, readmission due to angina pectoris, urgent revascularization, and stent thrombosis (defined as definite or probable according to the Academic Research Consortium) were also assessed.

Statistical analysis {#Sec7}
--------------------

The planned sample size was 500 patients based on the estimated number of patients who were anticipated to receive treatment with prasugrel and on enrollment feasibility. We enrolled consecutive patients in each institution to avoid patient selection bias. For each of the safety and efficacy variables, a point estimate and its 95% confidence interval (CI) were calculated.

The Chi-square test was used for subgroup analyses to identify clinical characteristics potentially affecting the incidence of bleeding AEs. The significance level was set to *α* = 0.05 (two-sided). All statistical analyses were performed with SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec8}
=======

Patient disposition and baseline demographic and clinical characteristics {#Sec9}
-------------------------------------------------------------------------

CRFs were collected from 749 patients at 98 institutions nationwide (Fig. [1](#Fig1){ref-type="fig"}). Of these, 732 patients were included in the safety analysis set, excluding those who fell under "breaches of contract" and "protocol deviations". All 732 patients were included in the efficacy analysis set. The mean (±standard deviation) observation period was 64.9 ± 73.8 days \[median (range) 31.0 (1--531) days\], regardless of continuation or discontinuation of prasugrel treatment.Fig. 1Patient disposition. *ACS* acute coronary syndrome

Baseline demographic and clinical characteristics of patients are shown in Table [1](#Tab1){ref-type="table"}. In the study population, 60.0% of patients had STEMI. Furthermore, 6.7% of patients had severe cardiovascular disease, classified as Killip Class IV. These patients were excluded from PRASFIT-ACS \[[@CR8]\], a phase III clinical trial conducted in Japanese patients with ACS.Table 1Baseline demographic and clinical characteristics of patientsPRASFIT-Practice I\
*N* (%)\
(*N* = 732)\[Reference\]\
PRASFIT-ACS\
*N* (%)\
(*N* = 685)Sex Male560 (76.5)536 (78.2)Age (years) ≥75221 (30.2)165 (24.1) Mean ± SD67.0 ± 12.465.4 ± 11.4 Median (range)67 (29--97)65 (32--95)Body weight (kg) ≤5094 (12.8)85 (12.4) Mean ± SD63.8 ± 12.564.2 ± 12.3Final diagnosis STEMI439 (60.0)340 (49.6) NSTEMI92 (12.6)187 (27.3) Unstable angina198 (27.0)156 (22.8)Killip classification Class I572 (78.1)NA Class II91 (12.4) Class III15 (2.0) Class IV49 (6.7)Exclusion criteriaMedical history Prior MI71 (9.7)34 (5.0) Prior revascularizations92 (12.6)40 (5.8) Prior CABG7 (1.0)6 (0.9) Prior TLR33 (4.5)15 (2.2) Prior ischemic stroke37 (5.1)Exclusion criteriaComplications Hypertension559 (76.4)495 (72.3) Dyslipidemia565 (77.2)516 (75.3) Diabetes mellitus267 (36.5)250 (36.5) History of smoking249 (34.0)273 (39.9) On dialysis15 (2.0)Exclusion criteriaAntithrombotic agent Prasugrel + aspirin678 (92.6)685 (100.0) Prasugrel + aspirin + WF or DOAC19 (2.6)Exclusion criteria Prasugrel + NSAIDs (w/o aspirin)11 (1.5)Exclusion criteriaConcomitant drug PPIs347 (47.4)282 (41.2)Stent type Drug-eluting stent671 (91.7)291 (42.5)Puncture site Brachial23 (3.1)22 (3.2) Radial374 (51.1)285 (41.6) Femoral315 (43.0)366 (53.4)*SD* standard deviation, *STEMI* ST-segment elevation myocardial infarction, *NSTEMI* non-ST-segment elevation myocardial infarction, *MI* myocardial infarction, *CABG* coronary artery bypass graft, *TLR* target lesion revascularization, *WF* warfarin, *DOAC* direct oral anti-coagulant, *NSAIDs* non-steroidal anti-inflammatory drugs, *PPIs* proton pump inhibitors, *NA* not available

Regarding other clinical characteristics that were excluded from the PRASFIT-ACS \[[@CR8]\], 5.1% of patients had a history of ischemic stroke; 2.0% were on dialysis; 2.6% were concomitantly using warfarin or direct oral anti-coagulants (DOACs); and 1.5% were using non-steroidal anti-inflammatory drugs (NSAIDs). The radial puncture site was the most common in the present observational study, though the femoral puncture site was the most common in PRASFIT-ACS \[[@CR11]\].

Treatment status of prasugrel and discontinuations {#Sec10}
--------------------------------------------------

Treatment status of prasugrel and discontinuations are shown in Fig. [2](#Fig2){ref-type="fig"}. An initial LD was administered to 95.1% of patients. In the majority of patients, the LD was given before the initial PCI. In 99.0% of patients, the initial prasugrel LD was 20 mg. One out of 690 (0.1%) patients was given an MD of 2.5 mg/day; the remaining patients received an MD of 3.75 mg once-daily.Fig. 2**a** Timing of loading, loading dose (LD), and starting maintenance dose (MD); **b** duration of prasugrel treatment and reasons for discontinuation. *PCI* percutaneous coronary intervention, *CABG* coronary artery bypass grafting

Almost one-half of the patients completed or discontinued the treatment within 1 month. The most common reason for discontinuation was switching to other anti-platelet agents (70.2%, 354/504). Of 504 patients, 40 (7.9%) discontinued prasugrel treatment because of AEs.

Safety and efficacy {#Sec11}
-------------------

### Safety {#Sec12}

The incidence of ADRs was 8.6% (63/732); serious ADRs, 3.4% (25/732); and bleeding AEs, 6.4% (Electronic Supplement 2). The most common ADRs were gastrointestinal disorders (e.g., gastrointestinal hemorrhage) \[3.3% (24/732)\]. The most common serious ADRs were also gastrointestinal disorders \[2.0% (15/732)\]. Table [2](#Tab2){ref-type="table"} summarizes the breakdown of bleeding AEs. Bleeding AEs occurred in 6.4% of patients. The most common bleeding AE was gastrointestinal disorders (2.7%), followed by general disorders and administration site conditions (1.0%). Regarding puncture site bleeding (puncture site hemorrhage or vessel puncture site hematoma), the puncture site locations were femoral (three patients), radial (two patients), femoral + radial (one patient), and brachial (one patient). The incidence of major bleeding \[thrombolysis in myocardial infarction (TIMI) criteria\] AEs was 1.6%. Approximately 60% (7/12) of all major bleeding AEs were gastrointestinal disorders.Table 2Incidence of bleeding adverse events by severity and siteItemResultNo. of patients in the safety analysis set732No. of patients with bleeding AEs47No. of bleeding AEs52Incidence of patients with bleeding AEs (%)6.4No. of patients with major bleeding AEs12Incidence of patients with major bleeding AEs (%)1.6Type of bleeding AENo. of patients with bleeding AEs; No. of bleeding AEs^a^ (%)Classification of bleeding (TIMI)Major bleeding (*N* = 12)Minor bleeding (*N* = 15)Clinically relevant (*N* = 12)Other (*N* = 10)Blood and lymphatic system disorders5 (0.7)13--1 Anemia5 \[2\] (0.7)13--1Eye disorders1 (0.1)------1 Conjunctiva hemorrhage1 \[1\] (0.1)------1Cardiac disorder3 (0.4)----3-- Cardiac tamponade1 \[1\] (0.1)----1-- Myocardial hemorrhage2 \[2\] (0.3)----2--Vascular disorders2 (0.3)--1--1 Hematoma1 \[1\] (0.1)------1 Bleeding1 (0.1)--1----Respiratory, thoracic and mediastinal disorders3 (0.4)12 Epistaxis1 (0.1)----1-- Hemoptysis1 (0.1)----1-- Pulmonary hemorrhage1 \[1\] (0.1)1------Gastrointestinal disorders20 (2.7)7662 Hemorrhagic intestinal diverticulum1 (0.1)----1-- Gastrointestinal hemorrhage6 \[6\] (0.8)312-- Gingival bleeding1 (0.1)------1 Hematemesis1 (0.1)--1---- Hematochezia1 (0.1)----1-- Mallory-Weiss syndrome1 (0.1)--1---- Melena4 \[2\] (0.5)--121 Rectal hemorrhage2 \[2\] (0.3)2------ Upper gastrointestinal hemorrhage1 \[1\] (0.1)1------ Large intestinal hemorrhage1 \[1\] (0.1)--1---- Duodenal hemorrhage1 \[1\] (0.1)1------ Hemorrhoidal bleeding1 (0.1)--1----Skin and subcutaneous tissue disorders4 (0.5)--4---- Subcutaneous hemorrhage4 (0.5)--4----Renal and urinary disorders3 (0.4)111-- Hematuria3 \[1\] (0.4)111--General disorders and administration site conditions7 (1.0)22--3 Puncture site hemorrhage6 \[1\] (0.8)12--3 Vessel puncture site hematoma1 (0.1)1------Injury, poisoning and procedural complications3 (0.4)------3 Subcutaneous hematoma2 (0.3)------2 Wounds1 (0.1)------1For SOC, the number of patients with bleeding AEs was tabulated, and for preferred term, the number of bleeding AEs (i.e., the number of patients for each preferred term) was tabulated. MedDRA/J version 18.1*AEs* adverse events, *SOC* system organ class, *TIMI* thrombolysis in myocardial infarction^a^The number of patients for SOC and the number of bleeding AEs for each preferred term were tabulated. The number of serious bleeding AEs is specified in square brackets in the applicable cells

The incidence of bleeding AEs by clinical characteristics is shown in Table [3](#Tab3){ref-type="table"}. The incidence of bleeding AEs was significantly higher in female patients, patients aged 75 years or older, patients with low body weight (50 kg or less), patients with severe cardiovascular disease (Killip Class III or IV), patients without dyslipidemia, and patients with severe renal impairment (creatinine clearance less than 30 mL/min). The proportion of female patients weighing 50 kg or less who experienced bleeding AEs was 40.9% (9/22), compared with 16.0% (4/25) among male patients with bleeding AEs weighing 50 kg or less. Furthermore, puncture site hemorrhage and subcutaneous hemorrhage were reported more frequently in female patients \[2.9% (5/172) and 1.7% (3/172), respectively\], than in males \[0.2% (1/560) and 0.2% (1/560)\]. In contrast, variations in timing of the initial LD (before, during, or after PCI) did not significantly affect the occurrence of bleeding AEs.Table 3Incidence of bleeding adverse events by clinical characteristicPatients, *N*Patients with bleeding AEs, *N* (%)*P* value\*Safety analysis set73247 (6.4)--Sex Male56025 (4.5)\<0.0001 Female17222 (12.8)Age (years) \<7551122 (4.3)0.0004 ≥7522125 (11.3)Body weight (kg)^a^ ≤509413 (13.8)0.0008 \>5061030 (4.9)Final diagnosis^a^ STEMI43933 (7.5)0.4138 NSTEMI923 (3.3) UAP19811 (5.6)Killip classification^a^ Class I57229 (5.1)0.0302 Class II918 (8.8) Class III152 (13.3) Class IV497 (14.3)Prior MI^a^ Absent65344 (6.7)0.1983 Present712 (2.8)Prior revascularizations^a^ Absent63443 (6.8)0.1951 Present923 (3.3)Prior CABG Absent72547 (6.5)0.4862 Present70 (0.0)Prior TLR Absent69945 (6.4)0.9312 Present332 (6.1)Prior ischemic stroke^a^ Absent68845 (6.5)0.3508 Present371 (2.7)Hypertension Absent17311 (6.4)0.9694 Present55936 (6.4)Dyslipidemia Absent16720 (12.0)0.0009 Present56527 (4.8)Diabetes mellitus Absent46528 (6.0)0.5609 Present26719 (7.1)History of smoking^a^ Absent46236 (7.8)0.0841 Present24911 (4.4)Baseline Ccr^a^ (mL/min) Normal (\>80)2999 (3.0)0.0043 Mild (\>50 to ≤80)23818 (7.6) Moderate (≥30 to ≤50)979 (9.3) Severe (\<30)487 (14.6)Timing of loading^a^ Before PCI^b^53337 (6.9)0.5973 During PCI^c^713 (4.2) After PCI^d^613 (4.9)Prasugrel + aspirin Not used543 (5.6)0.7875 Used67844 (6.5)Prasugrel + aspirin + WF or DOAC Not used71345 (6.3)0.4595 Used192 (10.5)Prasugrel + NSAIDs (w/o aspirin) Not used72147 (6.5)0.3814 Used110 (0.0)PPIs Not used38523 (6.0)0.6035 Used34724 (6.9)*NSTEMI* non-ST-segment elevation myocardial infarction, *STEMI* ST-segment elevation myocardial infarction, *UAP* unstable angina pectoris, *MI* myocardial infarction; *CABG* coronary artery bypass graft, *TLR* target lesion revascularization, *Ccr* creatinine clearance, *WF* warfarin, *DOAC* direct oral anti-coagulant, *NSAIDs* non-steroidal anti-inflammatory drugs, *PPIs* proton pump inhibitors, *PCI* percutaneous coronary intervention\* *χ* ^2^ test^a^Body weight, Killip class, prior MI, prior revascularization, prior ischemic stroke, history of smoking, and timing of loading dose were unknown in 28, 5, 8, 6, 7, 21, and 31 patients, respectively. Three patients had a final diagnosis other than STEMI, NSTEMI, or UAP. Baseline Ccr was not calculated in 50 patients^b^Given before the initial balloon passage in PCI^c^Given from the initial balloon passage in PCI until discharge from the PCI room^d^Given after discharge from the PCI room

Of the above risk factors, each score for the following five main risk factors \[female sex, age of 75 years or older, low body weight (50 kg or less), severe cardiovascular disease (Killip Class III or IV), and severe renal impairment (creatinine clearance less than 30 mL/min)\] is defined as 1. We calculated the total risk score and the incidence of bleeding AEs. By this analysis (Fig. [3](#Fig3){ref-type="fig"}), we found that the bleeding risk increased sharply in patients who had four or all five risk factors.Fig. 3Bleeding adverse events by number of risk factors. *AEs* adverse events, *Ccr* creatinine clearance. \*The score of the risk factors was not calculated in 55 patients

### Efficacy {#Sec13}

The details of the efficacy analysis are shown in Table [4](#Tab4){ref-type="table"}. The incidence of MACE in the efficacy analysis was 1.9% during prasugrel treatment, and 3.1% up to the end of the observation period. Cardiovascular death was the most common MACE, occurring in 13 patients with an incidence of 1.8% at the end of the study period. Of these, eight patients had severe cardiovascular disease (Killip Class IV). The incidence of all-cause death was 1.1% during prasugrel treatment and 2.2% up to the end of the study. Cardiovascular death accounted for approximately three-fourths of all-cause death.Table 4Incidence of cardiovascular eventsEfficacy outcomesCumulative incidence (%) *N* = 732On treatmentUntil the end of the observation period (EAS)MACE14 (1.9)23 (3.1) CV death6 (0.8)13 (1.8) Non-fatal MI5 (0.7)5 (0.7) Non-fatal ischemic stroke3 (0.4)5 (0.7)All-cause death8 (1.1)17 (2.3)Non-fatal stroke3 (0.4)6 (0.8)Readmission due to angina pectoris4 (0.5)8 (1.1)Revascularization10 (1.4)16 (2.2)Stent thrombosis2 (0.3)5 (0.7)*EAS* efficacy analysis set, *MACE* major adverse cardiovascular events, *CV* cardiovascular, *MI* myocardial infarction

Discussion {#Sec14}
==========

This postmarketing observational study assessed the safety and efficacy of short-term treatment with prasugrel in patients with ACS in real-world clinical practice settings in Japan. We consider that this study provides relevant information in terms of the efficacy and safety of prasugrel as we included patients with severe cardiac disease (Killip IV) (6.7% of patients), history of ischemic stroke (5.1%), and severe renal impairment (on dialysis) (2.0%), as well as those concomitantly taking drugs that increase the tendency of bleeding AEs, such as warfarin/DOACs (2.6%) or NSAIDs (1.5%). Patients having these baseline demographics and/or taking these concomitant drugs (approximately one-sixth of the patients) were excluded from clinical studies in Japan, such as PRASFIT-ACS \[[@CR8]\].

In approximately 99% of patients, the initial prasugrel LD and MD were 20 and 3.75 mg, respectively; 95.1% of patients received an initial LD. Prasugrel was administered as described in the package insert \[[@CR10]\], and aspirin was used concomitantly in most patients. Nearly 70% of prasugrel treatment completions or discontinuations occurred as patients switched to other anti-platelet agents. Because prasugrel was only allowed to be prescribed for a period of 2 weeks during the first year after its launch, these patients were prescribed other anti-platelet agents for subsequent long-term treatment.

The incidence of ADRs was 8.6%, and the incidence of serious ADRs was 3.4%. The highest incidence of ADRs was for gastrointestinal disorders (3.3%). Most of the ADRs and serious ADRs were bleeding AEs. A total of 12 patients experienced major bleeding AEs. Approximately 60% (seven patients) of all major bleeding AEs were gastrointestinal disorders. This finding was consistent with the observation in a survey of clopidogrel (J-PLACE) in NSTEMI/unstable angina pectoris patients scheduled to undergo PCI \[[@CR12]\], which suggests that gastrointestinal disorders are the main bleeding AEs in ACS patients. Therefore, preventive measures for gastrointestinal disorders might be required. Aspirin is highly likely to be a contributor to the development of these gastrointestinal disorders \[[@CR13]\] and the prevention of low-dose aspirin-associated upper gastrointestinal injuries by proton pump inhibitors (PPIs) has been reported \[[@CR14]\]. However, in this study, the proportion of patients receiving PPIs was less than half (47.4%) of the total population assessed. Although no significant difference was noted in the incidence of bleeding AEs between patients treated with or without concomitant PPIs in this study, concomitant use of PPIs from the start of dual anti-platelet therapy seems essential for preventing gastrointestinal disorders, especially in high-risk patients.

The incidence of major bleeding AEs in patients treated with prasugrel was 1.9% in PRASFIT-ACS \[[@CR8]\], and was slightly lower in this study (1.6%). Furthermore, the incidences of minor bleeding AEs, clinically relevant bleeding AEs, other bleeding AEs, and all bleeding AEs were all lower in this study in comparison with PRASFIT-ACS \[[@CR8]\]. One possible explanation for these differences is that, in this study, intraoperative bleeding of the expected amount associated with invasive procedures, such as PCI, was not reported as an AE. Another possible explanation is that the observation period in this study differed from that in PRASFIT-ACS \[[@CR8]\].

Notably, the incidence of bleeding AEs in this study was significantly higher in female patients and patients with severe cardiovascular disease (Killip Class III or IV), in addition to patients aged 75 years or older, patients with low body weight (50 kg or less), and patients with severe renal impairment. For the elderly, patients with low body weight, and patients with severe renal impairment, prasugrel treatment should be administered with caution as specified in the "Careful Administration" section of the package insert. Women generally have lower body weight than men, and there are differences in skin tissue structure between the sexes. Therefore, the fact that a higher proportion of female patients reported subcutaneous hemorrhage is likely to be related to these observed sex differences. In fact, the second most common bleeding AE was general disorders and administration site conditions (e.g., puncture site hemorrhage) (1.0%); thus, measures to prevent puncture site bleeding might also be required. Results of the MATRIX Access study \[[@CR15]\], a clinical trial conducted in European ACS patients who were about to undergo CAG and PCI, suggested that radial access compared with femoral access decreased the net AEs through a reduction in major bleeding AEs and death. Furthermore, in PRASFIT-ACS, the incidence of puncture site bleeding during PCI was lower in the radial access route group than in the femoral access route group \[[@CR11]\]. In this study, there was no difference in the number of patients with puncture site bleeding AEs between groups undergoing PCI via different puncture sites, which was likely because the incidence of patients with puncture site bleeding AEs was low \[1.0% (7/732)\], even though it was the second most common bleeding AE. The reason for the low incidence of puncture site bleeding AEs may be that---in contrast with PRASFIT-ACS---the proportion of patients undergoing PCI via femoral access was lower (43.0%) than that undergoing PCI via radial access (51.1%). Therefore, radial access seems more appropriate for preventing puncture site bleeding. In this study, the timing of the LD did not appear to significantly affect the incidence of bleeding AEs.

Though the overall incidences of bleeding AEs were lower in this study in comparison with PRASFIT-ACS \[[@CR8]\], after calculating the total risk score in association with the incidence of bleeding AEs, we found that the risk of bleeding increased if patients had four or all five risk factors: "female sex", "age of 75 years or older", "body weight of 50 kg or less", "severe cardiovascular disease", and "severe renal impairment". Another study assessed the risk of bleeding in patients with ACS undergoing PCI abroad; these investigators concluded that patients with ACS have marked variability in the risk of bleeding according to sex, age, and serum creatinine, among other factors \[[@CR16]\]. A study by Saito et al. \[[@CR11]\], which examined periprocedural bleeding in relation to the access route for PCI in a Japanese sample, found that sex, body weight, and age were risk factors, observations that are in line with our findings. There is a possibility that the risk of bleeding will increase in the above-mentioned patients. However, an analysis adjusting for confounding effects on each risk factor was not performed. Furthermore, as a limited number of patients with severe cardiac dysfunction were evaluated in clinical trials (these patients were generally excluded), these patients will be evaluated in the ongoing PRASFIT-Practice II study, a long-term observational study in patients with ischemic heart disease.

The incidence of MACE was lower in the current study (3.1%) than in PRASFIT-ACS \[[@CR8]\] (9.4%). Conversely, the incidences of cardiovascular death (1.8%), all-cause death (2.2%), and non-fatal ischemic stroke (0.7%) were slightly higher in the current study than those in PRASFIT-ACS \[[@CR8]\] (1.3, 1.8, and 0.4%, respectively). The explanation for these differences may involve: (1) the difference in the duration of the observation period in each study, and (2) that PRASFIT-Practice I was an observational study reflecting the clinical use of prasugrel in a real-world setting. Thus, patients with severe conditions were included, whereas in the PRASFIT-ACS \[[@CR8]\], such cases were excluded. The incidence of non-fatal MI was low in this study, which may also explain the low incidence of MACE compared with PRASFIT-ACS \[[@CR8]\]. A possible reason for this may be that naturally occurring MI as well as events judged according to CAG findings and markers of myocardial injury, including creatine kinase-MB, were evaluated in PRASFIT-ACS \[[@CR8]\]; however, only cases of MI reported by investigators under the actual conditions of use were evaluated as events in this study.

This study had several limitations. Because the study was designed as a postmarketing observational study, only patients treated with prasugrel were evaluated. As this study aimed to assess the real clinical situation in Japan, patients were not subjected to strict exclusion criteria. The observation and follow-up periods varied for each patient. As this was a short-term study, the results are only applicable to patients treated during a short period. The length of the observational period was insufficient to collect an adequate number of cardiovascular events to thoroughly evaluate safety, especially in terms of risk factors. However, the long-term observational study "PRASFIT-Practice II" will address these issues.

Conclusion {#Sec15}
==========

Based on the results of this short-term clinical study in patients with ACS in a real-world acute setting, prasugrel administration at an LD of 20 mg and MD of 3.75 mg/day was considered to be acceptable for Japanese patients in terms of safety and efficacy.
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